Organogenesis to unveil 2025 earnings amid stock market struggles

Organogenesis Holdings Inc., a key player in regenerative medicine, will release its fourth-quarter and full-year 2025 financial results on February 26, 2026. The announcement will follow the close of the stock market, with a conference call scheduled for 5:00 p.m. Eastern Time to discuss performance and corporate updates.

The company specializes in advanced wound care, surgical, and sports medicine solutions. Its portfolio includes a range of regenerative products designed to meet diverse patient needs across treatment stages.

Since its last earnings report in February 2025, Organogenesis has faced challenges in the finance sector. At that time, its market capitalization stood at around $450 million, with shares trading near $4.00. By February 19, 2026, the market cap had fallen to roughly $320 million, and the stock price dropped to about $2.85—a decline of over 28%.

Investors and analysts can join the live webcast of the conference call. The event will be available via the company's investor relations page at investors.organogenesis.com.

The upcoming report will provide clarity on the company's financial health after a year of stock market pressures. Shareholders and market watchers will likely focus on any strategic updates shared during the call.